2 Highlights:  Exosomes populate the cerebrospinal fluid of preterm infants with posthaemorrhagic hydrocephalus  Exosomes found after intraventricular hemorrhage are from serum and brain  Micro-RNAs isolated from the exosomal fraction relate to development and disease Abstract Background
Exosomal-sized EVs were isolated by differential ultracentrifugation and TEM confirmed the presence of CD63 + and CD81 + exosomes. The micro-RNAs miR-9, miR-17, miR-26a, miR-124 and miR-1911 were detected within the exosome-enriched fraction and profiled over time.
Conclusion
This is the first reported characterisation of exosomes from the CSF of preterm infants with post-haemorrhagic hydrocephalus. Preterm infants (<32 weeks gestational age) are at risk of a serious brain injury, called germinal matrix haemorrhage -intraventricular haemorrhage (GMH-IVH).
GMH-IVH most commonly occurs in the first 48h after birth 1 and is thought to arise from rupture of the capillaries of the subependymal germinal matrix 2 . Despite improved neonatal care leading to better survival, the incidence of GMH-IVH has remained static 3 . Post-haemorrhagic hydrocephalus (PHH) is a serious complication of GMH-IVH and aspiration from a ventricular access device is used to relieve the excess cerebrospinal fluid (CSF) from the ventricles. GMH-IVH can lead to many moderate to serious comorbidities, such as cerebral palsy 4 . To date we lack predictive indicators to identify the level of the damage or the long-term outcomes of GMH-IVH. Exosomes are spherical cell-derived vesicles between 30-100nm in diameter 5 . The earliest evidence of exosomes came in the 1980s when the vesicular release of the intact transferrin receptor from maturing reticulocytes was observed in vitro 6 .
Exosomes are produced by almost all cell types including neurons, microglia, and dendritic cells in the CNS 7 . Exosomes fall under the category of extracellular vesicles (EV) which also includes microvesicles (also known as ectosomes) and apoptotic bodies 7, 8 . Their key difference is their mode of biogenesis and several features are used to identify them: Exosomes are actively released by cells as a product of the endocytic pathway and are typically considered to be 30-100nm in diameter;
microvesicles are a product of, probably passive, plasma membrane budding and range from 50-1000nm; while apoptotic bodies, a product of apoptosis, are typically 50-5000nm 5, 6, 8, 9 . Aside from size, exosomes differ in their selective enrichment in certain proteins including tetraspanins CD63, CD81, and CD9 10-13 .
Interest in exosomes has grown rapidly and they are now recognised as sophisticated means of long and short distance intercellular communication 9 . Systemic inflammation has been shown to increase the release of extracellular vesicles by the choroid plexus epithelium. These vesicles contain pro-inflammatory factorsincluding microRNAs-that directly cause the activation of astrocytes and microglia in the brain parenchyma 14 . Exosomes in the embryonic CSF have also been shown to modulate IGF signalling and promote Neural Stem Cell proliferation (NSC) 15 .
Exosomes have been proposed as promising non-invasive diagnostic tools for 16 , kidney diseases 17 and neurodegeneration 18, 19 but have not been explored in neonatal development and GMH-IVH/PHH.
Methods

Diagnosis of PHH and CSF collection
CSF was collected from preterm infants born at less than 32 weeks gestation treated for evolving posthaemorrhagic hydrocephalus (PHH) admitted to the regional Neonatal Intensive Care Unit at Southmead Hospital in Bristol, United Kingdom. Table S1 .
Nanoparticle Tracking Analysis
Unprocessed CSF nanoparticle size distribution and concentration was determined using the NanoSight NS300 (Malvern, Amesbury, UK). CSF was diluted in distilled water (final volume 1ml) to ensure an appropriate concentration of particles detectable by the instrument. Each sample was analysed in triplicate using video recordings each 3 minutes in duration.
Differential ultracentrifugation
Exosome isolation was based on the method described by Théry et al 21 and took place at 4°C unless otherwise stated. CSF was thawed in 1.5ml Eppendorf Tubes, vortexed, then centrifuged at 2000g for 10min, then again at 10,000g for 20min to pellet dead cells and cell debris. The supernatant was then transferred into 1.5ml
Beckman Ultracentrifuge Tubes (Beckman Coulter, London, UK) and ultracentrifuged in a fixed angle TLA-55 rotor (Beckman Coulter, London) at 100,000g (40,000 rpm) for 70min to pellet the exosomes. If a washing step was required, the exosomeenriched pellet was resuspended in PBS and ultracentrifuged as above. The pellet was resuspended in 100μl of filtered PBS and stored at -80°C until further analysis.
Repeat freeze-thaw cycles (> 2) were avoided. For a flow diagram of this method see Figure S1 .
exoEasy Maxi Kit extracellular vesicle purification
CSF was thawed in 1.5ml Eppendorf Tubes and vortexed. All spin columns, collection tubes, and reagents were supplied in the exoEasy Maxi kit (Qiagen, Manchester, UK) and isolation was performed according to the manufacturer's instructions. Briefly, CSF from each patient was added to Buffer XBP (1:1), mixed thoroughly, and allowed to reach room temperature. This was centrifuged through an exoEasy spin column (max 16ml/column) at 500g for 1min. Flow-through was discarded and the column washed through with 10mL buffer XWP centrifuged at 5,000g for 5min. The flowthrough was discarded and 400μl Buffer XE was added to the spin column, incubated at room temperature for 1min, then centrifuged at 500g for 5min, then again with the same eluate at 5,000g for 5min ( Figure S1 ) and the final eluate (400μl) was stored at -80°C until RNA extraction.
Transmission electron microscopy
Negative staining was adapted from a previously described method 22 . If immunogold labelling did not occur, 2μl of the EV-enriched sample was placed on a carbon-coated formvar film on a copper grid (300 mesh) (Agar Scientific, Stansted, UK) and left for 1 min. For all samples the grid was washed on a droplet of distilled water for 10sec prior to incubation in uranyl acetate (3% in dH20) (BDH Industries, Mumbai, India) and methyl cellulose (2% in dH20) (Sigma Aldrich) mixed in a ratio of 1:9 for 5min on ice. Using a loop to remove excess fluid, the grid was dragged across a Whatman 1 filter (GE Healthcare, Buckinghamshire, UK) and left to air-dry upright.
Immunogold labelling was adapted from a previously described method 22 . All incubations occurred at room temperature unless otherwise stated. Following exosome isolation 2μl of sample were placed onto a carbon-coated formvar film on a
copper grid (300 mesh) (Agar Scientific, Stansted, UK) and left for 2min. Grids were fixed and blocked by incubation for 5min per step on a drop of 1% paraformaldehyde (PFA) (Sigma Aldrich, Irvine, UK), then 50nM glycine in PBS (Gibco), followed by 0.1% bovine serum albumin (BSA-c) (Aurion, The Netherlands). Grids were then incubated with the selected primary antibody: anti-CD63 mAb (100μg/ml) or anti-CD81 mAb (200μg/ml) (both diluted 1:50 in 0.1% BSA and both Santa Cruz Biotechnology, Heidelberg, Germany) and left for at least 30min. Grids were washed 3 times in 0.1% BSA to prevent secondary staining, allowing 5min between washes, then incubated on a drop of secondary gold-conjugated goat anti-mouse IgG (Aurion) (6nm) (diluted 1:20 in 0.1% BSA/PBS) and left for at least 30min. Grids were washed 3 times and negatively stained as above.
All Grids were viewed and photographed using a FEI Tecnai 12 transmission electron microscope and images analysed using ImageJ.
Exosome size distribution measurements
15 randomly-taken electron micrographs per sample were analysed in ImageJ. EVs were identified as spherical/cup-shaped particles with the presence of a surrounding continuous membrane and the Feret's diameter of each EV was determined.
RNA extraction
Total RNA was extracted from EVs using the mirVana™ miRNA )solation Kit Ambion according to the manufacturer's instructions using reagents included in the kit. 500μl lysis/binding solution were added directly to pelleted exosomes to maximise RNA yield, then vortexed to lyse the exosomes. miRNA Homogenate Additive was added (1/10 the volume of the exosome lysate), vortexed, and incubated on ice for 10min.
500μl Acid-Phenol:Chloroform was added and vortexed, then centrifuged at 10,000g for 5min at room temperature (Eppendorf centrifuge 5430R). The upper aqueous phase was carefully removed and transferred to a fresh 1.5ml Eppendorf tube and x 1.25 volumes of 100% ethanol (Sigma Aldrich) was added. This mixture was passed through a Filter Cartridge by centrifuging at 10,000g for 15sec, and the Filter Cartridge washed with 700μl miRNA Wash Solution 1 by centrifuging at 10,000g for 15sec. This step was repeated twice with 500μl Wash Solution 2/3 with a final spin at 10,000g for 1min. The contents were eluted by passing 100μl of nuclease-free water (pre-heated to 95°C) through the Filter Cartridge and spun at maximum speed for 20-30sec. The eluate, containing total RNA, was stored at -20°C until further analysis.
Total RNA concentration was measured using the Nanotube 2000 spectrophotometer (Thermo Fisher). 
Data Analysis
Data were analysed using GraphPad Prism 6. Graphs were plotted  SD or  SEM as appropriate as specified in figure legends.
Results
CSF of preterm infants with PHH contains exosomes
Nanoparticle tracking analysis (NTA) is a widely used technique in the EV field to accurately determine the size distribution and concentration of nanoparticles in Figure 1 (A) demonstrates there is a heterogeneous population of particles within CSF, and that this varies between patients. The mean particle size was 106.90.44nm, 156.92.08nm, and 120.771.2nm for patients 1, 2, and 3 respectively. The modal particle sizes for patients 1 and 3 were similar: 86.2nm and 81.9nm while the modal particle size in patient 2 was 159.3nm. Different particle concentrations were observed across the three patients: 2.89x10 10 9.17x10 8 ; 1.13 x 10 11 3x10 9 and 3.47x10 10 6.96x10 8 particles/ml for patients 1, 2, and 3 respectively.
The concentration of particles that fit the size criteria for exosomes was similar across all three patients: 1.53x10 10 5.83x10 8 ; 1.59x10 10 5.29x10 8 and 1.48x10 10 5.15x10 8 particles/ml were within 30-100nm for patients 1, 2 and 3 respectively. It is likely that this represents a low estimate for small-EV concentration as, due to the limits of refraction, this analysis under-samples small vesicles (<45nm).
Interestingly, although CSF from patient 2 contained the highest total concentration of particles, only 14.1% was within the exosomal range compared to 53% and 42.5% in patient 1 and patient 3 respectively (Figure 1 (B) ). To further this characterisation, we focused on patient 3 as CSF samples were obtained throughout the treatment course. NTA of whole CSF taken at five time points revealed the heterogeneous population of EVs within CSF (Figure 2 (A) ). Exosomesized particles were detected in all samples of CSF. At 25, 32 and 54 days old the modal particle sizes were within the range of exosomes (83.6nm, 81.9nm and 85.4nm respectively). At 29 and 124 days the modal particle size was above the size criteria for exosomes (104.6, and 122.6nm respectively). The mean particle sizes were 113.601.70nm, 132.401.82nm, 120.771.82nm, 119.33.24nm, 135.250.55nm, and 162.601.57nm for 25, 29, 32, 54, and 124 days. Interestingly, both the overall particle concentration and the proportion of particles within 30-100nm range appear to show a gradual decrease with the GMH-IVH treatment progression (Figure 2 (B) ).
CSF particle profiling over the course of four months following PHH
While the mean (R 2 =0.801, p=0.016) and modal (R 2 =0.744, p=0.027) particle size increases with time following PHH (Figure 2 (C) ).
A C C E P T E D M A N U S C R I P T
CD63 + and CD81 + exosomes are present in the CSF of premature infants following PHH
NTA cannot distinguish between EVs and similar sized particles which lack a lipid membrane, therefore we used TEM to qualitatively characterize these vesicles. We (Figure 3 (A-C) ).
Of note, following isolation via the exoEasy kit, the final eluate appeared cloudy and large precipitates were observed under electron microscopy ( Figure S2) . A total of 265 EVs were counted across the 3 patients, which ranged from 23.1nm to 214.9nm in diameter. For patients 1-3, the modal particle sizes were 42.5nm (x̅ =53.523.8nm), 42.5nm (x̅ =75.539.2nm) and 32.5nm (x̅ =42.118.5nm) respectively ( Figure S3 ). All modal particle sizes were within 30-100nm suggesting that the majority of nanoparticles purified following exosome isolation are within the size range of exosomes. As expected, larger particles are removed by the 10,000 g spin and therefore both modal and mean particle sizes following purification were lower than the original values obtained with NTA.
The exosome-enriched fraction of CSF contains miRNA
A C C E P T E D M A N U S C R I P T
After demonstrating the presence of exosomes in CSF, based on morphology, size and positive immunogold labelling, we aimed to isolate exosomal RNA. Following exosome isolation, total RNA was extracted from all samples. Ultracentrifugation and ultracentrifugation with a washing step yielded similar levels of RNA at 0.20.004ng/μl and 0.160.042ng/μl respectively. Exosome isolation using the exoEasy kit yielded the most RNA at 0.470.324ng/μl, but final RNA concentrations were remarkably variable ( Figure S4 ). To determine whether exosomal miRNAs are present in the CSF of patients with infantile PHH, five miRNAs (previously shown to be present in CSF/serum 23 ) were selected and quantified by qPCR. These miRNAs were miR-17 (serum-specific), miR-26a (highly expressed in CSF exosomes), miR-124 (brain-specific), miR-9 (brain specific and known regulator of neurogenesis 28 ) and miR-1911 (brain specific, highly enriched in CSF exosomes). Mature miRNA sequences are detailed on Figure 4 expression showed a general increase over the four months following PHH (Figure 4 (B)). Following the confirmation that exosome-sized nanoparticles were present in PHH-CSF, we sought to further characterise them using TEM since NTA cannot distinguish between exosomes and similarly sized particles which lack a membrane. TEM revealed spherical vesicles with a continuous membrane that were CD63 + and CD81 + supporting the presence of exosomes in PHH-CSF.
However, it is important to keep in mind that one of the primary limitations in However, further investigation is needed to ascertain whether the decline in CSF particle concentration is specific to PHH, or occurs as a consequence of perinatal development.
We then attempted to isolate exosomal RNA from our CSF samples. Following that found only ~1 miRNA to every 121 exosomes 33 . We then hypothesised that exosomal miRNA expression might change over time following GMH-IVH, as
such, we performed qPCR on a panel of five miRNAs. miR-9 is an important regulator of neurogenesis, involved in coordinating both differentiation and proliferation of NSCs 34, 35 . miR-26a has been shown to induce neurite outgrowth in rats; an essential process during neuronal migration and differentiation during development 36 . Expression of both miR-9 and miR-26a remained constant over the four months following PHH. This was unexpected considering their implications in neuronal development but suggest that they would not be suitable biomarkers for GMH-IVH progression. miR-17 is a serum-specific miRNA 23 . We observed a negative correlation between miR-17 and time following PHH. Disruption of the blood brain barrier (BBB) and/or direct bleeding at the time of injury in GMH-IVH, leads to serum contamination and therefore abnormal expression of miR-17 in early CSF samples. A progressive reduction of miR-17 CSF levels could reflect restoration of the BBB integrity. miR-124 is a highly conserved and abundantly expressed, brain-specific miRNA 37 . miR-124 expression has been shown to increase during neuronal development in line with maturation of neurons in a rat model 38 . However, in our cohort mir-124 expression was negatively correlated with time following PHH which could underpin some of the developmental impairment seen in GMH-IVH patients. miR-1991 was selected as a brain-specific miRNA, found to be highly enriched in CSF exosomes. The increase in miR-1911-5p following GMH-IVH and the development of PHH make this an interesting potential biomarker. To our knowledge, this is the first evidence of exosomes and exosomal miRNA expression in PHH-CSF. We have demonstrated the presence of a heterogeneous population of EVs in PHH-CSF which includes CD63 + and CD81 + exosomes. We have shown that the exosomal concentration decreases over the course of four months following PHH and that these exosomes contain miRNA that may present themselves as potential biomarkers for PHH. These miRNAs are critical for brain development and therefore may reflect patient responses to treatments or the pathological processes occurring in the development or resolution of PHH.
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